HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Futura’s Revolutionary ED Treatment One Step Closer To US And EU OTC Approval

Executive Summary

US and EU OTC approval for Futura's drug-free erectile dysfunction treatment MED3000 edges closer, following the company's submission of its EU dossier and a second pre-submission meeting with the FDA. 

You may also be interested in...



Pfizer's Upjohn Breaking The Silence Around ED With New Viagra Connect Campaign In UK

Pfizer is investing roughly $10m in Viagra Connect in the UK to help raise awareness of erectile problems among the country's male population. 

Watch Out Viagra! UK’s Futura Set To Shake Up Global ED Market With MED3000

HBW Insight talks exclusively to Futura Medical about its new erectile dysfunction product MED3000, which it says could take the global OTC market by storm. 

Perrigo To Launch UK Private-Label Viagra Connect Competitor

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel